PFG Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.61M | Buy |
22,305
+212
| +1% | +$45.6K | 0.28% | 76 |
|
|
2026
Q1 | $4.81M | Buy |
22,093
+2,854
| +15% | +$633K | 0.23% | 105 |
|
|
2025
Q4 | $4.4M | Sell |
19,239
-12,741
| -40% | -$2.9M | 0.21% | 107 |
|
|
2025
Q3 | $7.4M | Buy |
31,980
+2,577
| +9% | +$525K | 0.3% | 81 |
|
|
2025
Q2 | $5.46M | Buy |
29,403
+3,062
| +12% | +$569K | 0.25% | 82 |
|
|
2025
Q1 | $5.52M | Buy |
26,341
+3,972
| +18% | +$772K | 0.31% | 80 |
|
|
2024
Q4 | $3.98M | Sell |
22,369
-2,330
| -9% | -$428K | 0.24% | 94 |
|
|
2024
Q3 | $4.88M | Sell |
24,699
-1,272
| -5% | -$237K | 0.31% | 76 |
|
|
2024
Q2 | $4.45M | Buy |
25,971
+1,006
| +4% | +$167K | 0.3% | 77 |
|
|
2024
Q1 | $4.55M | Sell |
24,965
-1,905
| -7% | -$328K | 0.33% | 68 |
|
|
2023
Q4 | $4.16M | Buy |
26,870
+202
| +0.8% | +$29.4K | 0.34% | 74 |
|
|
2023
Q3 | $3.98M | Sell |
26,668
-3,074
| -10% | -$451K | 0.36% | 70 |
|
|
2023
Q2 | $4.01M | Buy |
29,742
+2,738
| +10% | +$402K | 0.31% | 88 |
|
|
2023
Q1 | $4.3M | Buy |
27,004
+2,397
| +10% | +$366K | 0.36% | 70 |
|
|
2022
Q4 | $3.98M | Buy |
24,607
+5,824
| +31% | +$893K | 0.39% | 56 |
|
|
2022
Q3 | $2.52M | Sell |
18,783
-103
| -0.5% | -$14.8K | 0.29% | 93 |
|
|
2022
Q2 | $2.89M | Buy |
18,886
+495
| +3% | +$75.6K | 0.33% | 66 |
|
|
2022
Q1 | $2.98M | Sell |
18,391
-1,007
| -5% | -$146K | 0.3% | 70 |
|
|
2021
Q4 | $2.63M | Buy |
19,398
+298
| +2% | +$35.2K | 0.26% | 108 |
|
|
2021
Q3 | $2.06M | Buy |
19,100
+902
| +5% | +$103K | 0.23% | 131 |
|
|
2021
Q2 | $2.05M | Buy |
18,198
+442
| +2% | +$49.8K | 0.23% | 132 |
|
|
2021
Q1 | $1.92M | Buy |
17,756
+436
| +3% | +$46.6K | 0.25% | 126 |
|
|
2020
Q4 | $1.86M | Buy |
17,320
+610
| +4% | +$58.6K | 0.31% | 89 |
|
|
2020
Q3 | $1.46M | Sell |
16,710
-1,036
| -6% | -$97.5K | 0.28% | 104 |
|
|
2020
Q2 | $1.72M | Buy |
17,746
+473
| +3% | +$41.6K | 0.39% | 81 |
|
|
2020
Q1 | $1.45M | Buy |
17,273
+841
| +5% | +$71.6K | 0.39% | 83 |
|
|
2019
Q4 | $1.47M | Buy |
16,432
+139
| +0.9% | +$11.5K | 0.36% | 90 |
|
|
2019
Q3 | $1.2M | Buy |
16,293
+437
| +3% | +$30K | 0.33% | 98 |
|
|
2019
Q2 | $1.07M | Buy |
15,856
+2,469
| +18% | +$194K | 0.29% | 109 |
|
|
2019
Q1 | $1.06M | Sell |
13,387
-1,053
| -7% | -$86.1K | 0.32% | 97 |
|
|
2018
Q4 | $1.15M | Buy |
+14,440
| New | +$1.27M | 0.36% | 91 |
|
|
2018
Q2 | – | Sell |
-3,881
| Closed | -$367K | – | 142 |
|
|
2018
Q1 | $367K | Buy |
3,881
+87
| +2% | +$9.56K | 0.35% | 80 |
|
|
2017
Q4 | $367K | Buy |
+3,794
| New | +$358K | 0.38% | 73 |
|
Other funds holding ABBV
ATO
PFG Advisors's ABBV Position: Q2 2026 in Review
PFG Advisors increased its AbbVie (ABBV) stake by 0.96% in Q2 2026, buying an estimated $45.6K and bringing the position to 22,305 shares worth $5.61M. The position accounts for 0.28% of the portfolio, ranked #76.
PFG Advisors first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $7.4M in Q3 2025. 1,758 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- PFG Advisors held 22,305 shares of AbbVie worth $5.61M as of Q2 2026.
- PFG Advisors bought 212 AbbVie shares in Q2 2026, an estimated $45.6K.
- AbbVie made up 0.28% of PFG Advisors's portfolio in Q2 2026, its #76 holding.
- PFG Advisors first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
- PFG Advisors's AbbVie position peaked at $7.4M in Q3 2025.
- 1,758 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on PFG Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.